ASX Announcement

19 November 2025

Chairman's Address to 2025 Annual General Meeting

Sydney, Australia – 19 November 2025: OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to provide the Chairman's address to today's Annual General Meeting to be held at K&L Gates Level 25, 525 Collins Street, Melbourne.

Chairman's Address

Good morning everyone.

On behalf of the entire Board of OncoSil Medical Limited, it is my pleasure to welcome our Shareholders to the Company's Annual General Meeting (AGM) for the financial year ended 30 June 2025 (FY25).

The AGM is always a key event in our corporate calendar. It provides an opportunity for your Board to highlight OncoSil Medical's achievements over the past year and update Shareholders on the Company's future plans. Importantly, the AGM also gives you, our Shareholders, the opportunity to ask questions of your Board about OncoSil Medical's recent and future performance.

It is my pleasure to deliver my first Chairman's Address to the 2025 AGM of OncoSil Medical. I am honoured to have joined the Board in July 2025 firstly as a Non-Executive Director, and since 1 October 2025 as your Chairman. Our mission is clear at OncoSil. We aim to expand access to a differentiated, targeted radiation option for patients with pancreatic cancer, a disease which continues to have one of the lowest survival rates of any major oncology indication. We are really at the early stages of our journey, with significant upside potential to grow the number of treatments we sell over time through existing market penetration and new market access.

FY25 was an important year for OncoSil Medical. It was a period characterised by significant regulatory progress, strengthening of our clinical position, targeted commercial expansion, and critical steps taken to strengthen the Company's capital position. Together, these achievements form a strong platform as we move into FY26 and advance towards broader commercial adoption.

A key highlight of the year was the approval from German Federal Joint Committee (G-BA) for a fully funded clinical trial in Germany. The G-BA is Germany's highest decision-making body for healthcare reimbursement, and this approval and successful completion of the clinical trial will broaden access for the OncoSil™ device across the German public hospital system. A successful completion of the clinical trial paves the way for further reimbursement negotiations in other EU member states and beyond, as the G-BA decision is often referenced by peer health systems. It also serves to further validate the clinical strength of our data and positions the OncoSil™ device as a credible and scalable cancer therapy option in one of the world's most

advanced healthcare environments. We expect to commence the clinical trial under the G-BA in the first half of calendar year 2026 and hence the commencement of meaningful revenues. We appreciate investors patience with this initiative, which has taken longer than expected, however it will mean a significant step up in treatments, which will be reimbursed at a full commercial rate for OncoSil. The commencement of the G-BA clinical trial will further serve as a platform to increase commercial treatments at participating clinical trial centres.

In parallel during the year, we saw a sharp increase in German hospital applications for NUB approvals, which rose by over 40% year-on-year. NUB is a hospital-led process to secure temporary, hospital-specific extra reimbursement for new inpatient treatments. It provides the basis by which hospitals may negotiate with German statutory health insurance organisations reimbursement for the clinical treatment of patients. This approval serves to unlock access to funding in Europe's largest market. Our first commercial sale in Germany was recorded in October.

A second key highlight of the year was the successful achievement of Medical Device Regulation (MDR) certification for the OncoSil™ device, granted in late January 2025 by our EU Notified Body, the British Standards Institute or BSI. MDR approval removes prior post-market restrictions and significantly streamlines treatment initiation in both the EU and the UK. It shortens sales cycles, reduces administrative friction for hospitals, and importantly strengthens our ability to scale in major European markets.

This regulatory success represents years of disciplined investment in quality systems, manufacturing, and clinical validation, and the entire OncoSil Medical team should be commended for their commitment to delivering this outcome.

Our global clinical footprint continued to deepen throughout FY25.

At Digestive Disease Week 2025 in San Diego, investigators from the Royal Adelaide Hospital presented a comparative study showing superior outcomes for OncoSil™ relative to stereotactic body radiation therapy (SBRT). The analysis demonstrated improved median overall survival—22 months compared with 14 months for SBRT—extended progression-free survival, and a favourable safety profile. This independent analysis, delivered at a major global gastro-oncology congress, adds considerably to the emerging evidence base supporting our technology.

By the end of June 2025, the PANCOSIL and TRIPP-FFX clinical trials reached 95% and 99% recruitment respectively, with both studies fully recruited in July 2025. These trials are central components of our long-term evidence strategy, and the Board was highly encouraged by the pace of enrolment and investigator engagement globally.

In the case of PANCOSIL, in September 2025 we reported that OncoSil therapy is safe and feasible to deliver by CT-guided percutaneous administration. The PANCOSIL trial results were presented by Dr. Danielle Vos from Amsterdam University Medical Center at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2025 Congress, in Barcelona, Spain. Preliminary Median overall survival from diagnosis was 20.6 months, comparing favourably with LAPC survival rates of approximately 13 months.

We undertook several capital raises during FY25 totalling more than $14 million, and as at 30 September 2025, being the most recent quarter, held $5.9 million in cash and cash equivalents. We thank all investors for their support in those capital raises, which allows the company to continue to invest capital in the areas of clinical trials, market development, and regulatory engagement. In addition, the Company received a $1.1 million R&D tax incentive during the third quarter of FY2025, which further strengthened our capital base and supported ongoing investment in clinical research and device innovation. We anticipate a $1.8 million R&D tax incentive for the FY25 period to be received prior to the end of the calendar year or early in 2026.

In June 2025 Shareholders approved a 1-for-400 consolidation of the Company's issued capital. This important step simplifies our register, improves comparability with sector peers, and positions the Company for stronger engagement with both domestic and international investors.

The Board continued to evolve to ensure we maintain the right blend of governance, commercial expertise, and industry knowledge as we scale. In January 2025, we welcomed Ms Lel Smits as a Non-Executive Director. Ms Smits brings deep experience in corporate communications, governance, and strategic engagement developed through advising over 500 ASX-listed companies. I have already mentioned my appointment to the Board.

We thank our previous Non-Executive Director Dr Gabriel Liberatore for his contribution to OncoSil along with Douglas Cubbin who is retiring from the Board following today's meeting. On behalf of all Shareholders, we extend our sincere thanks to them both for their strategic insights, governance and dedicated service.

On behalf of the Board, I thank our Shareholders for their ongoing support and belief in our mission. I also acknowledge the dedication of our staff, clinicians, trial investigators, and commercial partners worldwide. Their commitment is central to everything we have achieved this year.

OncoSil Medical's purpose is clear—to make a meaningful impact for patients with pancreatic cancer. With your support, we are executing with focus and discipline to ensure the OncoSil™ device becomes an important part of the global therapeutic landscape.

Thank you.

Dr Thomas Duthy
Chairman

Ends.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	**Mr. Tim Luscombe & Mr. David Wood** Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670	**Ms. Julia Maguire** **The Capital Network** Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Greece, Turkey, and Israel.

To learn more, please visit: www.oncosil.com/

1. https://gco.iarc.fr/en

OncoSil™

Intratumoural placement of ^{32}P for locally advanced pancreatic cancer

Targeted Approach • Positive Impact

Nigel Lange, 19 November 2025

Disclaimer

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com for further information.

Not an Offer for Securities

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction.
This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this presentation should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of law. Please refer to the international offer restrictions section of this presentation.

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or in any jurisdiction in which such offer would be illegal. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold , directly or indirectly, in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Forward-Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved.
In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Disclaimer

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

The information contained in this presentation is current as at 19 November 2025.

Corporate Overview

OncoSil Medical | 13 November 2025	
GICS:	Health Care – Pharmaceuticals, Biotechnology & Life Sciences (Life Sciences Tools & Services)
ASX code:	OSL
Market cap:	$24.7 million
Shares on Issue:	18.83 million
Share price:	$1.31 (as at 13-Nov-25)
52-week high:	$3.60
52-week low:	$0.80
Average daily volume:	31,654
Free float:	66.2%
Cash on Hand (30-Sep-25)	$5.92 million

OncoSil Medical Major Shareholders | 13 November 2025	
Washington H. Soul Pattinson (Pengana Capital Group Limited)	18.18%
State Street Australia Ltd (Australian Ethical Investment Limited)	6.93%
TOP 20	54.0%

Experienced Board and Management

Depth in Interventional Oncology and Nuclear Medicine Commercialisation

Dr Thomas Duthy
Non-executive Chairman

20+ years of experience across financial markets, corporate development and board-level roles, involved in numerous successful M&A transactions.

Nigel Lange
Managing Director & CEO
Executive Director

30+ years' experience in medical device industry.

Served as Group COO and Interim Group CEO of Sirtex Medical (ASX:SRX).

Lel Smits
Non-executive Director

Award-winning entrepreneur, director and investor relations advisor, serving as a Director on Australian Shareholders' Association since 2021.

Shelley Steyn
Chief Financial Officer

Extensive experience in senior accounting, commercial and financial analysis, and audit roles across listed and private companies.

Dr Jon Bell MD
Chief Medical Officer

12 years' experience as consultant interventional radiologist and an internationally recognised expert in interventional oncology.

Renzo DiCarlo
Head of Transformation

A proven nuclear medicine executive Renzo brings over 25 years' experience in therapeutic drugs and medical devices.

Recent Achievements



Executive Summary

Commercialising targeted radiotherapy for pancreatic cancer

- OncoSil Medical is commercialising the OncoSil™ device, an implanted device (brachytherapy) delivering targeted radiation (^{32}P) to pancreatic tumours
- OncoSil™ device is now **approved for sale in over 34 countries** via CE Mark
- **Commercial ramp-up** has commenced in FY26, driven by significant growth in existing European markets
- **Increasing market access** via label expansion combining new delivery methods and new chemotherapy combinations[1]
- **Platform technology** can be leveraged into other cancer indications (Bile duct cancer, liver, glioblastoma)
- Experienced Board & Management team in the commercialisation of interventional oncology devices

>US$4.2bn global addressable market with no competition[3]

- Granted **Breakthrough designation** in the EU, UK and US with extensive **patent coverage** across all key geographies
- Large global pancreatic cancer patient population of ~510k p.a and targeting locally unresectable population of ~153k (~30%) with the **market expected to increase by 37% by 2035**[2]
- Negligible survival improvement in over 20 years with <12% survival rates at 5-years and 8.5 months median overall
- Patient recruitment completed for **PANCOSIL** & **TRIPP-FFX** trials, targeting:
  - ✓ **Percutaneous** delivery to drive market access and clinical adoption globally
  - ✓ Label expansion in addition to standard-of-care chemotherapy (**FOLFIRINOX**)

References: 1. Subject to Regulatory Approval. 2. Globocan 2022 data . 3 179,000 global locally advanced pancreatic cancer population multiplied by US$24k average price

Executive Summary

Significant achievements over CY25

- Received **MDR Approval** which includes the removal of all existing post-market restrictions (OSPREY registry)
- Patient recruitment completed for **PANCOSIL** study and preliminary data presented at CIRSE 2025 Congress (a groundbreaking delivery method for OncoSil™ device)
- Patient recruitment completed for **TRIPP-FFX** trial (to expand OncoSil™ device label with additional chemotherapy combination)
- Second manufacturing facility in **Sydney**, Australia activated and ready to undergo validation.
- Constructive discussions with US **FDA** on the regulatory pathway for OncoSil™ device in Bile Duct Cancer (dCCA)
- German Federal Joint Committee (**G-BA**) tender process underway to appoint a CRO
- First patient treatments completed at **Germany** and **Portugal**

Catalyst rich CY25/26

- Strong **commercial momentum** and **growing hospital adoption** across existing markets: Austria, Germany, Greece, Israel, Italy, Portugal, Spain, Turkey, and the UK
- **Tender finalisations** expected to drive significant revenue growth
- Finalisation of **G-BA** tender process to appoint CRO and commence recruitment for the G-BA trial
- Label expansion targeting:
  - **Percutaneous delivery** for Interventional Radiology (PANCOSIL study)
  - Combination with standard-of-care chemotherapy - **FOLFIRINOX** (TRIPP-FFX study)
- First commercial production at **Sydney** manufacturing facility (H1 CY26)
- **Publication of real-world clinical data** to support market access and drive adoption
- Accelerating commercial activities through expanded market access and new geographic opportunities across the **Nordics** and **MENA** regions[1]
- TGA Approval – in review

References: 1. Subject to Regulatory Approvals.

Pancreatic Cancer Prognosis has Remained Unchanged for 40 Years[1]



Survival rates are very poor:

- 8.5 months overall median survival
- <12% reach 5-year survival[2]
- Lower survival rate than any other cancer[3]
- The number of cases and deaths both estimated to increase by 40% before 2035[3]

New therapeutic options urgently needed

References: 1. Cancer Research UK. www.cancerresearchuk.org/health-professional/cancer-statistics/survival/common-cancers-compared#heading-Three (accessed September 2024).
2. American Cancer Society. Cancer Facts & Figures 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf. 3. United European Gastroenterology. Pancreatic Cancer Across Europe: Taking a united stand. https://ueg.eu/files/771/b7ee6f5f9aa5cd17ca1aea43ce848496.pdf.

Pancreatic Cancer Stage at Diagnosis

Surgical resection remains the only potentially curative treatment for pancreatic cancer[1]



30% of LAPC patients show metastatic progression within 3-6 months[9,10]

Abbreviations: CT: Chemotherapy; ICT: Induction chemotherapy; CCRT: Concurrent chemoradiation therapy.

References: 1. Ducreux M et al. Ann Oncol 2015; 26 (Suppl 5): v56–68. 2. van Dam JL et al. Eur J Cancer. 2022; 160: 140–149. 3. Chang JS et al. Cancer Res Treat 2018; 50: 562–574 (suppl data). 4. Burris HA 3rd et al. J Clin Oncol 1997; 15: 2403–2413. 5. Von Hoff DD et al. N Engl J Med 2013; 369: 1691–1703. 6. Conroy T et al. N Engl J Med 2011; 364: 1817–1825. 7. Balaban EP et al. J Clin Oncol 2016; 34: 2654–2668. 8. National Comprehensive Cancer Network (NCCN) Clinical Practive Guidelines in Oncology: Pancreatic adenocarcinoma. Version 1.2020. 9. Huguet et al. J Clin Oncol 2010. 10. Mukherjee et al, Lancet Oncol 2013.

OncoSil™ Device

Driving increased resection rates, downstaging, survival benefits and quality of life

OncoSil™ is intended for the treatment of **locally advanced unresectable pancreatic cancer,** in addition to gemcitabine-based chemotherapy *(combination with FOLFIRINOX currently in trials)*

OncoSil™ is a **single-use** brachytherapy device comprised of microparticles and a diluent



OncoSil™ is currently implanted directly into a pancreatic tumour via injection under **endoscopic ultrasound** guidance

98% of all radiation is delivered within **81 days** of injection causing damage to cancer cell DNA and **killing malignant cancer cells with no damage to surrounding tissue**

Requires only one supervised procedure given simplicity and familiarity with standard, everyday, biopsy procedures

Percutaneous delivery is transformational and anticipated to significantly accelerate market penetration:

- ✓ Expanding the number of treating clinicians to include Interventional Radiologists
- ✓ Broader patient access and points of care
- ✓ Outpatient day procedure – complete within 20 minutes
- ✓ Conscious sedation (patient awake)

Patient recruitement at PANCOSIL study completed and preliminary data presented at CIRSE 2025 Congress

Targeting H2 CY26 to make OncoSil™ commercially available to Interventional Radiologists

Growing Body of Evidence

4 clinical studies supporting commercialisation demonstrate efficacy, safety and tolerability in LAPC

	Unresectable Locally Advanced Pancreatic Cancer (LAPC)				Unresectable LAPC or Borderline-Resectable LAPC		Metastatic PDAC
Study	PanCO Study [1]	OncoPaC-1 Study [2]	Propensity Score Weighted Landmark Analysis [3]		Comparative Analysis [4]		Metastatic Study [5]
Treatment	OncoSil™ + Chemotherapy [a]	OncoSil™ + gemcitabine/ nab-paclitaxel	OncoSil™ + Chemotherapy [b]	*vs.* Chemotherapy [b] (± Chemoradiotherapy)	OncoSil™ + Chemotherapy [b]	*vs.* Chemotherapy [b] + SBRT	OncoSil™ + Chemotherapy [a]
Sample Size	42 (50 ITT)	9	50 35 at landmark	54 51 at landmark	42	59	14
Local Disease Control Rate at 16 weeks	90.5%	77.8%	nr	nr	nr	nr	100%
Objective Response Rate	31.0%	22.2%	nr	nr	nr	nr	57.1%
Disease Control Rate	100%	100%	nr	nr	nr	nr	100%
Surgical Resection with Curative Intent	23.8%	0	28.6%	p=0.03 12.1%	22%	p<0.001 0%	7.1%
Downstaging	33.3%	not reported	31.4%	p=0.03 13.6%	23.8%	p=0.003 3.4%	7.1%
Local PFS, median	9.8 months	27.3 months	15.6 months	p=0.006 9.3 months	18.9 months	HR 0.62 p=0.040 14.1 months	12.2 months
Distant PFS or PFS (PFS), median	9.3 months PFS	12.2 months PFS	14.2 months	p=0.058 10.7 months	20.0 months	HR 0.59 p=0.023 14.0 months	9.2 months PFS
Overall Survival, median	15.5 months	27.3 months	20.0 months	p=0.002 12.3 months	22 months	HR 0.45 p=0.014 14 months	13.8 months

Key: [a] Gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy; [b] gemcitabine/nab-paclitaxel, gemcitabine or FOLFIRINOX chemotherapy; **Abbreviations:** LAPC, locally advanced pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival.
Use of OncoSil™ for borderline-resectable LAPC or metastatic pancreatic ductal adenocarcinoma (mPDAC) is off-label.

References: 1. Ross PJ et al. Results of a single-arm pilot study of ^{32}P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/ nab-paclitaxel or FOLFIRINOX chemotherapy. *ESMO Open* February 2022; 7 (1): 100356. 2. OncoSil Medical Ltd. Data on file. 3. Lim A et al. Combined phosphorus-32 implantation and chemotherapy alone for locally advanced pancreatic cancer: a propensity-score weighted landmark analysis. *Gastrointest Endosc* 2025 May 8. 4. Lim A et al. Comparison of combined chemotherapy and stereotactic body radiation therapy with combined chemotherapy and phosphorus-32 microparticle intra-tumoural implantation in patients with locally advanced pancreatic adenocarcinoma. Presented at Digestive Disease Week (DDW2025) scientific meeting in San Diego, USA, 3–6 May 2025.
5. Lim A et al. Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma. *iGIE* 2024 July 2; ePub 1–9.

Significant Commercial Opportunity

Existing Priority Markets			
Target Market	Pancreatic Cancer Incidence p.a.[1]	Locally Advanced Pancreatic Cancer[2]	Market Opportunity (A$m)[3]
UK	11,852	3,556	138
Spain	9,282	2,785	108
Italy	16,111	4,833	188
Germany	22,587	6,776	264
Greece	2,343	703	27
Austria	2,250	675	26
Turkiye	9,012	2,704	105
Portugal	2,217	665	26
Israel	1,249	375	15
Total (Existing)	76,903	23,071	898
Near-Term Target Markets			
South Korea	10,046	3,014	117
France	16,538	4,961	193
Denmark	1,454	436	17
Finland	1,570	471	18
Norway	1,275	383	15
Switzerland	2,056	617	24
Saudi Arabia	666	200	8
Hong Kong	1,116	335	13
Netherlands	3,689	1,107	43
Belgium	2,433	730	28
Total (New)	40,843	12,253	477

OncoSil™ device remains at the early-stage of commercialization in existing geographies with ~A$898m market size

Expanding to ~A$1,375m addressable market over next 18 –24 months

Market Penetration expected to now accelerate over the near-term driven by:

- Percutaneous Delivery following a target H2 CY26 label expansion
- Commencement of Patient Recruitment for the G-BA Trial

Reference: 1. Globocan 2025 data. 2 Calculated as 30% of Pancreatic Cancer Incidence. 3 Local Price in EUR converted to AUD (EURAUD) 1.77

Accelerating Commercialisation

Enhancing market access via label extension

Program	Description	Key Milestones	Commercial Impact
PANCOSIL	Feasibility and safety of CT-guided percutaneous radionuclide therapy with OncoSil™ device + Chemotherapy in non-progressive locally advanced pancreatic cancer	• Patient recruitment completed • Initial results were presented at CIRSE 2025 • Regulatory submission target of Q1 CY26 – Added to Label and targeted commercial launch in EU and UK markets in H2 CY26	Accelerates market penetration with lower barriers to adoption via a new method of delivery for a new medical speciality (Interventional Radiology)
TRIPP-FFX	Efficacy and Safety of Oncosil combined with standard FOLFIRINOX chemotherapy *vs.* FOLFIRINOX chemotherapy alone	• Patient recruitment completed • Results expected at H1 CY26 • Target Regulatory submission H2 CY26 • Added to Label in all approved jurisdictions H2 CY26	Accelerates market penetration with label expansion to include coverage of OncoSil™ device in addition to standard-of-care chemotherapy (FOLFIRINOX)
Bile Duct Cancer	Bile Duct Cancer (Distal Cholingiocarcinoma - dCCA) For approval by US FDA under Human Device Exemption (HDE)	• Discussions remain ongoing and constructive with US FDA • OncoSil submitted additional data to support HDE application	Small addressable market however a supportive pathway to US market entry for LAPC

13

Unlocking Market Potential in Germany

Commercial significance of G-BA Trial and beyond



- ✓ Public insurance reimbursement for OncoSil™ device in Germany for trial participants
- ✓ Opportunity to participating hospitals to receive reimbursement for patients not participating in trial
- ✓ 5 hospitals already received positive decision from public health funds to start OncoSil™ treatments before G-BA trial starts

Unlocking Market Potential in Germany

Commercial significance of G-BA Trial and beyond



The top 50 German pancreatic cancer centers performed approximately **5,000** complex pancreatic surgeries in 2024[1], accounting for **43%** of all such procedures nationwide.

These high-volume centers represent our primary targets for commercial adoption, alongside their anticipated participation in the G-BA trial[2].

References: **1.** https://www.aok.de/pp/hintergrund/mindestmengen/mindestmengen-transparenzkarte-2026/ **2.** The centers with appropriate nuclear medicine facilities capable of delivering OncoSil™ device.

Unlocking Market Potential in Europe

Accelerating growth in existing territories

Country	Key Milestones	Commercial Importance
Spain	• OncoSil™ available in 11 hospitals • 6 hospitals routinely ordering and treating with OncoSil™ • Over 70 patients treated with OncoSil™ device until now	• Largest revenue-contributing market • Strong referral acceptance from oncologists and surgeons • Strong growth in usage and revenue
Italy	• 5 hospitals routinely ordering and treating with OncoSil™ • First tender agreement signed, further tenders to be finalized in Q1 CY26	• OncoSil™ adopted by two leading hospitals — University of Verona and San Camillo Forlanini Hospital • Revenue contribution expected to increase significantly in H1 CY26 following finalisation of individual tender agreements
Greece	• 1 hospital routinely ordering and treating with OncoSil™ • Training underway at 2 additional hospitals	• Significant revenue contributor despite small population size • Intention to publish local real-world data
Israel	• 1 hospital routinely ordering and treating with OncoSil™ • Training underway at 2 additional hospitals	• OncoSil™ approved by Clalit Health Services — second largest health insurer in Israel • Despite logistical challenges, treatment well accepted by key opinion leaders (KOLs) and integrated in clinical practice
Turkey	• 3 hospitals routinely ordering and treating with OncoSil™ • Training completed at 6 hospitals; first patient treatments pending	• 45% resection rate in real-world setting • One of the largest potential markets in oncology and nuclear medicine treatments • Ongoing referral education initiatives to increase patient flow

Outlook

Commercial ramp up with upside expected from new market access initiatives

Unit volumes are expected to ramp up materially following onboarding activities in existing initial markets in CY26

Volumes in existing markets are expected to underpin growth from market entry expectations over the near-term

OncoSil™ has an aspirational target of 5–10% market penetration in existing and near-term target markets implying up to 3,532 units p.a.

Label expansion activities enhancing market access including:

- Percutaneous delivery method for new clinician group (Interventional Radiologists); and
- Combination with FOLFIRINOX chemotherapy

Market Penetration	5%	7.5%	10%
Units	1,766	2,649	3,532
Revenue (A$m)	69	103	138

This is provided for illustrative purposes only. It is not a forecast nor is there any guarantee that the market penetration, unit sale pricing or sales volume could or will be achieved. It also assumes regulatory product approvals which have not been obtained. As illustrative - it should not be relied upon in making an investment decision.

Upcoming Milestones

Significant catalysts over the next 12 months



References: 1. Indicated in Distal Chalingiocarcinoma. 2. Subject to regulatory Review. 3. Subject to approval following PANCOSIL study.

Technology & Innovation

Macquarie Cyclotek site

- ✓ Macquarie Operations in process of final validation (95% complete) – completion target Q1 CY26
- ✓ New Target from ANSTO being used in the validation with more capacity, quality and versatility. Quartz Ampoule from Mo-Sci fully implemented.
- ✓ The site is ready to receive, process and measure Hot Target.
- ✓ New dispensing doses of 50, 100, 150 and 250 Mbq are being validated for therapy.
- ✓ Cyclotek ISO 13485 process have started – completion target H1 2026.
- ✓ The R&D target schedule has been developed with ANSTO, Lucas Heights. ANSTO has agreed to increase reactor spots to meet growing demand.

Nigel Lange

CEO & Managing Director

E: nigel.lange@oncosil.com

Learn more about OncoSil Medical:

- Website
- ASX announcements
- LinkedIn

Targeted Approach • Positive Impact